FIELD: medicine, pharmaceutical industry. SUBSTANCE: alpha-fetoprotein is dissolved and polyglucin or rheopolyglucin at concentration 4-30 mg/ml is added followed by packaging into ampoules or flasks and lyophilic drying. One ampoule has 0.06-0.09 mg alpha-fetoprotein and 4-30 mg polyglucin or rheopolyglucin. EFFECT: simplified process, increased stability of the end product. 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREPARING ALPHA-FETOPROTEIN PREPARATION | 2000 |
|
RU2170586C1 |
METHOD OF ALPHA-FETOPROTEIN PREPARATION PREPARING | 2000 |
|
RU2169578C1 |
METHOD OF ALPHA-FETOPROTEIN PREPARATION PREPARING | 1998 |
|
RU2123009C1 |
METHOD OF ALPHA-FETOPROTEIN PREPARING | 1995 |
|
RU2100031C1 |
MEDICATION COMPOSITION AND METHOD OF ITS OBTAINING FOR TREATMENT OF CHRONIC VIRAL HEPATITIS B OR C AND AIDS | 2010 |
|
RU2440133C2 |
METHOD FOR PREPARING ALPHA-FETOPROTEIN PREPARATION TABLET | 2005 |
|
RU2319479C2 |
METHOD FOR PREPARING PREPARATION DRY ALPHA-FETOPROTEIN | 2005 |
|
RU2283131C1 |
METHOD FOR PRODUCTION OF ALPHA-FETOPROTEIN | 2006 |
|
RU2308286C1 |
METHOD TO TREAT MALIGNANT NEOPLASMS AND COMBINED PREPARATION OF ANTITUMOR ACTION TO PERFORM THE METHOD | 2000 |
|
RU2179452C1 |
METHOD OF TREATING CONDITIONS CHARACTERIZING BY AUTOIMMUNE AGGRESSION | 1995 |
|
RU2137477C1 |
Authors
Dates
1998-11-10—Published
1996-06-03—Filed